FOURIER study : we have to treat the LDL target

10 april 2017

The FOURIER study has finally revealed its results !

The study yielded the positive result that the antibody PCSK9 evolocumab (Repatha®, Amgen), administered alongside a statin against the placebo, significantly lowered the primary criterion, which was a composite of cardiovascular events (cardiovascular mortality, non-fatal myocardial infarctions and strokes, coronary revascularisation and unstable angina), by 15%, after an average monitoring duration of 26 months. A significant reduction of 20% was observed in the secondary composite criterion of 3 points (cardiovascular mortality, non-fatal myocardial infarctions and strokes), of 27% in myocardial infarctions and 20% in ischemic strokes, but no trend was observed in the reduction of cardiovascular mortality or of an overall reduction.

FOURIER, multinational study (49 countries, 1242 sites), randomised, double-blind carried out on 27764 subjects with a proven atherosclerotic illness (history of myocardial infarction, stroke, PAD), and aged 40 to 85 years (75% male) and already on statins. It included two “active” groups receiving different doses of evolocumab: 140 mg 1/15 days or 420 mg 1/month and a placebo group.

FOURIER has confirmed LDL causality (we no longer refer to LDL hypothesis!). The only downside is that the study was not long enough (? 2 years), which explains the lack of benefit for cardiovascular mortality. We should also note that lowering LDL-cholesterol on average to 0.30 mg/dL (a level not achieved so far) is both beneficial on a cardiovascular level and also well-tolerated.

Given the current controversies, these results clearly confirm the “LDL target” and the absolute necessity to treat hypercholesterolemia.

More info  : Sabatine MS, & al. N Engl J Med. 2017 Mar 17 and Diapos de présentation des résultats to the American College of Cardiology congress 2017.

Privacy Preference Center


Ce cookie est utilisé pour identifier une session utilisateur, il ne contient aucune données personnelles.

This cookie is used to identify a user session, it does not contain any personal data.


Analyse de traffic

Ces cookies servent à l'analyse de trafic du site.

These cookies are used to analyze the site's traffic.



Ces cookies servent au bon fonctionnement du site en multilingue, notamment dans le but d'afficher le site dans la langue la plus adaptée pour vous.

These cookies are used for the proper functioning of the site in multilingual, especially for the purpose of displaying the site in the language most suitable for you.

_icl_current_language, wpml_referer_url